PharmaCyte Biotech, Inc. (PMCB)
NASDAQ: PMCB · Real-Time Price · USD
1.300
+0.010 (0.78%)
Apr 2, 2025, 4:00 PM EDT - Market closed

PharmaCyte Biotech Cash Flow Statement

Millions USD. Fiscal year is May - Apr.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2015 - 2019
Period Ending
Jan '25 Apr '24 Apr '23 Apr '22 Apr '21 Apr '20 2015 - 2019
Net Income
20.250.33-4.32-4.24-3.55-3.83
Upgrade
Asset Writedown & Restructuring Costs
22----
Upgrade
Loss (Gain) From Sale of Investments
-10.131.57----
Upgrade
Stock-Based Compensation
0.410.670.650.110.441.22
Upgrade
Other Operating Activities
-14.99-7.030.17--0.08-
Upgrade
Change in Accounts Payable
00.26-0.240.03-0.010.06
Upgrade
Change in Other Net Operating Assets
0.180.04-0.05-0.02-0.130.2
Upgrade
Operating Cash Flow
-2.27-2.15-3.79-4.12-3.33-2.34
Upgrade
Other Investing Activities
--5----
Upgrade
Investing Cash Flow
-7-5----
Upgrade
Long-Term Debt Issued
-----0.08
Upgrade
Total Debt Issued
-----0.08
Upgrade
Long-Term Debt Repaid
----0.05-0.06-0.01
Upgrade
Total Debt Repaid
----0.05-0.06-0.01
Upgrade
Net Debt Issued (Repaid)
----0.05-0.060.06
Upgrade
Issuance of Common Stock
-0087.364.72.66
Upgrade
Repurchase of Common Stock
-3.55-28.2-13.56---
Upgrade
Financing Cash Flow
-35.55-10.71-13.5687.314.642.73
Upgrade
Foreign Exchange Rate Adjustments
-0-0-0.0100-0.01
Upgrade
Net Cash Flow
-44.83-17.86-17.3683.21.310.38
Upgrade
Cash Interest Paid
---000
Upgrade
Cash Income Tax Paid
-0-000
Upgrade
Levered Free Cash Flow
-3.36-2.55-3.52-2.62-1.97-1.03
Upgrade
Unlevered Free Cash Flow
-3.36-2.55-3.52-2.62-1.97-1.03
Upgrade
Change in Net Working Capital
0.96-0.850.13-0.010.15-0.14
Upgrade
Updated Mar 17, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q